Alentis Therapeutics

Alentis Therapeutics is a clinical-stage biotechnology company based in Basel, Switzerland, that develops monoclonal antibodies and antibody-drug conjugates targeting Claudin-1 for the treatment of fibrotic diseases and CLDN1-positive solid tumors. The enterprise has successfully raised approximately $366 million in total venture funding to advance its proprietary drug candidates through Phase 1 and Phase 2 clinical trials. This accumulated capital includes a $105 million Series C financing in 2023 and a $181.4 million round in 2024, which marked the largest private financing in Switzerland for that year. The company's clinical pipeline is supported by a syndicate of prominent institutional investors, including Novo Holdings, RA Capital Management, Jeito Capital, and OrbiMed. Currently led by Chief Executive Officer Mark Pruzanski, Alentis Therapeutics was founded in 2019 by Professor Thomas Baumert based on his research at the University of Strasbourg.